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Docosahexaenoic acid; ECM, Extracellular matrix; EPA, Eicosapentaenoic acid; FGF2, 
basic fibroblast growth factor; GMP, granulocyte-macrophage progenitor; GUSB, β-
glucuronidase; HDL, High density-lipoprotein; HFD, high fat diet; HI-FCS, heat-inactivated 
fetal calf serum; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; 
HSP90AB1, heat shock protein HSP 90-β; IL, Interleukin; LIF, Leukaemia inhibitory factor; 
LDL, low-density lipoprotein; LK, Lin- Sca-1- c-Kit+; LSK, Lin- Sca-1+ c-Kit+; MDSC, Myeloid-
derived suppressor cells; MEP, megakaryocyte-erythroid progenitor; MDA, 
malondialdehyde; MI, Mycocardial infarction; MPP, multipotent progenitors; NR1H3, 
Nuclear receptor subfamily 1 group H member 3; ox, oxidized; PE, phycoerythrin; PPAR, 
peroxisome proliferator-activated receptor; PS, Phytosterols; PUFA, polyunsaturated fatty 
acids; PVAT, Perivascular adipose tissue; REDUCE-IT, Reduction of Cardiovascular Events 
With Icosapent Ethyl–Intervention Trial; ROS, reactive oxygen species; SELPLG, Selectin 
P ligand; SLAM, Signaling lymphocytic activation molecule; SOD, superoxide dismutase; 
TBHP, tert-butyl hydroperoxide; TG, Triglycerides; TNF, tumor necrosis factor 
 















































































































Atherosclerosis, an inflammatory disorder of the vasculature and the underlying 
cause of cardiovascular disease, is responsible for one in three global deaths. Consumption 
of active food ingredients such as omega-3 polyunsaturated fatty acids, flavanols and 
phytosterols have many beneficial effects on cardiovascular disease. However, their 
combined actions on risk factors for atherosclerosis remains poorly understood. We have 
previously shown that a formulation containing each of these active components at 
physiologically relevant doses modulated several monocyte/macrophage processes 
associated with atherosclerosis in vitro, including inhibition of cytokine-induced pro-
inflammatory gene expression, chemokine-driven monocyte migration, expression of M1 
phenotype markers, and promotion of cholesterol efflux. The objective of the present study 
was to investigate whether the protective actions of the formulation extended in vivo and to 
delineate the potential underlying mechanisms. The formulation produced several 
favourable changes, including higher plasma levels of HDL and reduced levels of 
macrophages and myeloid-derived suppressor cells in the bone marrow. The mRNA 
expression of liver-X-receptor-, peroxisome proliferator-activated receptor- and 
superoxide dismutase-1 was induced in the liver and that of interferon- and the chemokine 
(C-X-C motif) ligand 1 decreased, thereby suggesting potential mechanisms for many 
beneficial effects. Other changes were also observed such as increased plasma levels of 
triglycerides and lipid peroxidation that may reflect potential activation of brown fat. This 
study provides new insights into the protective actions and the potential underlying 
mechanisms of the formulation in vivo, particularly in relation to risk factors together with 
changes in systemic inflammation and hepatic lipid alterations associated with 
atherosclerosis and metabolic syndrome, and supports further assessments in human trials.
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Cardiovascular disease (CVD), including myocardial infarction (MI) and 
cerebrovascular accident, is the leading cause of global morbidity and mortality.1 According 
to the Heart Disease and Stroke Statistics 20201, CVD accounted for 17.8 million deaths per 
year in 2017. This figure is expected to increase to more than 23.6 million by 2030 in part 
due to a rise in risk factors such as obesity and diabetes together with the acquisition of a 
sedentary westernized lifestyle in developing countries.1-3 This will continue to impose 
enormous economic burden on the healthcare system and hence it is important to develop 
new approaches for the prevention of CVD. The annual direct and indirect cost of CVD in 
the United States from 2014 to 2015 was estimated to be $351.3 billion.1 It is projected that 
between 2015 and 2035, this will remain relatively stable for 18- to 44-year olds, increase 
slightly for 45- to 64-year olds and increase substantially for those that are over 65 years of 
age.1
Atherosclerosis, an inflammatory disease of medium and large arteries associated 
with the accumulation of lipids and fibrous elements, is the underlying cause of CVD.2-4 The 
accumulation of Apolipoprotein (Apo)B-containing lipoproteins, particularly low-density 
lipoproteins (LDL) in the intima of arteries is a major instigator of atherosclerosis.2-4 The 
modification of LDL, particularly oxidation to form oxidized (ox)-LDL, together with other risk 
factors cause activation or dysfunction of the nearby endothelial cells.2-4 This is associated 
with an inflammatory response characterized by the secretion of chemokines by endothelial 
cells and increased expression of adhesion proteins on their cell surface.2-4 The net result 
of such changes is the recruitment of immune cells, particularly monocytes, to the site of 
oxLDL accumulation in the intima of arteries.2-4 The recruited monocytes then differentiate 
into macrophages, which begin to uptake oxLDL via receptor- and non-receptor mediated 
mechanisms to transform into lipid-laden foam cells.2-4 Accumulation of intracellular 
cholesterol due to such increased uptake of oxLDL together with reduced efflux of the sterol 














































































































to high density-lipoprotein (HDL) particles, and hence decreased reverse cholesterol 
transport to the liver, eventually leads to lysis of the foam cells by apoptosis and necrosis.2-4 
This results in the development of a lipid-rich necrotic core in the arterial wall that then 
causes a chronic inflammatory response regulated by cytokines.2,5-8 Smooth muscle cells 
migrate from the media to the intima and produce an extracellular matrix (ECM) to stabilize 
the atherosclerotic plaque.2-4 Excessive degradation of the ECM by a range of proteases 
produced by the different cells in the plaque under inflammatory conditions causes plaque 
destabilization, which can ultimately lead to its rupture and subsequent thrombosis and 
clinical complications such as MI.2-6 Approaches that modulate lipid homeostasis and the 
inflammatory response represent promising avenues for therapeutic intervention.
Current therapies against atherosclerosis such as statins, which lower LDL-
cholesterol and have additional pleiotropic actions, are associated with considerable 
residual risk for CVD.2-4 In addition, many patients are unable to achieve target LDL-
cholesterol levels even with the maximum dose of statins or are susceptible to the various 
side effects such as rhabdomyolysis and increased risk for developing type 2 diabetes.2,3 In 
terms of alternative therapies, some success has been seen recently with cholesterol 
absorption inhibitor ezetimibe, and expensive monoclonal antibodies that target proprotein 
convertase subtilisin/kexin type 9, a protease involved in the degradation of the LDL 
receptor, and the cytokine interleukin (IL)-1.2,3 However, many promising pharmaceutical 
agents for the treatment of CVD identified from various drug discovery programs [e.g. 
inhibitors of cholesterol ester transfer protein, lipoprotein-associated phospholipase A2] 
have produced disappointing outcomes in clinical trials because of off-target effects and/or 
safety concerns2,3,9, thereby emphasizing the need to develop other agents for disease 
prevention and therapeutic intervention.
Consumption of various food ingredients is associated with favourable cardiovascular 
health.3,4 For example, fish oils rich in omega-3 polyunsaturated fatty acids (PUFA), such as 














































































































eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), reduce CVD via multiple 
actions, including reducing plasma cholesterol levels and dampening inflammation.3,4 
Indeed, the recent Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention 
Trial (REDUCE-IT) of 8,179 participants showed that in patients with elevated levels of 
triglycerides (TG) despite the use of statins, the risk of CVD was significantly lower in those 
receiving 2 g of icosapent ethyl (ethyl-EPA) twice daily compared to the placebo 
control.10 Similarly, flavanols such as catechins present in cocoa have been shown to reduce 
risk factors for CVD in pre-clinical studies and small clinical trials.3 Phytosterols (PS) are 
plant sterols and stanols that compete with cholesterol for the intestinal uptake of dietary 
and biliary cholesterol.3,4 An epidemiological study involving 22,256 individuals showed 
direct correlation between diets rich in PS and reduced plasma LDL.11 Similarly, a meta-
analysis of 41 trials demonstrated approximately 10% reduction of plasma LDL with daily 
consumption of 2 g of PS.12
Although many studies have investigated the cardiovascular benefits of individual 
food components, very few have analyzed combinations in their natural context that delivers 
physiological doses of the active ingredients.3,4 We have previously investigated the action 
of a combination of omega-3 PUFA-rich fish oil, flavanol-rich cocoa extract and mixed PS in 
a readily absorbable emulsified format13,14 at a physiologically relevant dose on several key 
monocyte/macrophage processes associated with atherosclerosis in vitro.15 The formulation 
produced inhibition of chemokine-driven monocyte migration, cytokine-induced expression 
of key genes implicated in inflammation and macrophage polarization to a pro-inflammatory 
M1 phenotype, and enhanced cholesterol efflux from foam cells.15 However, it’s important 
to extend the findings on beneficial effects in vitro to an in vivo context given the potential 
differences in metabolic transformations and other actions that are likely to exist. The effect 
of the formulation in vivo has not been analyzed and formed the focus of the current acute 
study in C57BL/6J mice fed a high fat diet (HFD) for 3 weeks. The experimental approach 














































































































was similar to our previous study in C57BL/6J mice fed a HFD for 2 weeks that demonstrated 
many beneficial actions of probiotics.16 The impact on several risk factors associated with 
atherosclerosis and metabolic syndrome was investigated, including the weight of mice and 
various fat depots; plasma levels of lipoproteins, reactive oxygen species (ROS) and key 
cytokines; hematopoietic stem and progenitor cell profiles in the bone marrow; and the 
expression of disease-associated genes in the liver. Our hypothesis was that the formulation 
will produce beneficial changes in risk factors associated with atherosclerosis and metabolic 
syndrome such as reduced plasma levels of LDL/VLDL, pro-inflammatory cytokines and 
markers of oxidative stress, increased plasma levels of HDL and anti-inflammatory 
cytokines, and anti-inflammatory immune cell profile in the bone marrow. 
2. Materials and Methods
2.1. Materials
All chemicals were from Sigma-Aldrich (Poole, UK) unless otherwise stated.
2.2. Animal experiments
All studies and protocols were approved by the Cardiff University Institutional Ethics 
Review Committee and the United Kingdom Home Office, and experiments were performed 
in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication 
No. 85–23, revised 1996; Experimental licence 30/3365). 
Male C57BL/6J mice were housed in a light and temperature-controlled facility (lights 
on 7 am to 7 pm, 22°C). A total of 13 mice (8-week-old) were included in this study and 
assigned to two groups in standard cages and received daily gavage in the morning of either 
the vehicle (6 mice) or the formulation (7 mice) for 3 weeks with ad libitum access to a HFD 
[21% (w/w) pork lard and 0.15% (w/w) cholesterol; Special Diet Services, Witham, UK].16 














































































































The number of animals and the duration of HFD feeding are similar to our previous study on 
probiotics (6 mice per group and 2-week HFD feeding) that demonstrated many beneficial 
anti-atherogenic changes.16 The formulation delivered 410 mg/kg of omega-3 PUFAs 
EPA/DHA, 410 mg/kg of PS and 41 mg/kg of flavanols in an emulsified format13,14 (equating 
to approximate human doses of 2 g EPA/DHA, 2 g PS and 200 mg flavanols according to 
Nair and Jacob).17 The key active ingredients in the formulation were EPA, DHA, catechins, 
Stigmasterol, Campsterol, Sitosterol and Brassicasterol.15  The vehicle control was xanthan 
gum used as an emulsifying agent in the formulation. 
Body weight was determined at the start of the study, following assignment to the two 
groups, and then approximately every 2 days. Food intake was controlled (i.e. the same 
weight of food was given per mouse per day), thereby allowing weight gain over time 
between the formulation and control mice to be determined. At the end of the study, all mice 
were sacrificed under anaesthesia (carbon dioxide) by cardiac puncture and death 
confirmed by palpitation. Blood from cardiac puncture was collected into tubes containing 
heparin and the plasma obtained by centrifugation (12,000 x g) for 10 min. Rear legs were 
removed for bone marrow extraction and placed into tubes containing PBS supplemented 
with 2% (v/v) heat-inactivated fetal calf serum (HI-FCS) for cell population analysis. The fat 
pads and organs were weighed and snap frozen in liquid nitrogen and stored at -80°C.
2.3. Plasma lipid analysis
The plasma levels of total cholesterol, LDL/VLDL and HDL were determined using 
the Cholesterol Assay Kit -HDL and LDL/VLDL (ab65390) and TG were measured using the 
Triglyceride Assay Kit (ab65336) according to the manufacturer’s instructions (Abcam, 
Cambridge, UK). 
2.4. Plasma ROS and malondialdehyde (MDA) levels 














































































































The plasma levels of ROS and MDA were determined using the OxiSelect in vitro 
ROS/RNS Assay Kit (ROS quantification) and TBARS Assay Kit (MDA quantification) 
according to the manufacturer’s instructions (Cell Biolabs Inc, San Diego, USA).
2.5. Plasma cytokine levels
Plasma cytokine levels were determined by the Central Biotechnology Services 
(School of Medicine, Cardiff University, UK) using a V-PLEX Plus Pro-inflammatory Panel 1 
Mouse Kit that provides assay-specific components for the quantitative determination of 
multiple cytokines in biological samples (e.g. 50 l plasma) according to the manufacturer’s 
instructions (Meso Scale Discovery, Maryland, USA). 
2.6. Analysis of hematopoietic cell populations within the bone marrow
The tibia and femur were homogenized with PBS supplemented with 2% (v/v) HI-
FCS and filtered through a 70 μm filter. The total number of cells was then determined and 
10 million, 8 million and a further 1 million cells were used to analyze the signaling 
lymphocytic activation molecule (SLAM), progenitor cell populations and cell lineage 
populations respectively. These numbers reflect the abundance of different populations in 
the bone marrow and to allow accurate determination of their frequency by counting all 
possible events.
The cells were stained at 4°C for 30 min with a biotinylated mix of lineage marker 
antibodies (CD3e, CD4, CD8a, B220, Gr1, Mac1, Ter119) present within the SLAM and 
progenitor cell populations (see Table S1 for sources of all the antibodies) along with specific 
antibodies. The antibodies for the analysis of the SLAM cell population were: phycoerythrin 
(PE)/cyanine7 (Cy7)-conjugated anti-mouse CD150; FITC-conjugated anti-mouse CD48; 
allophycocyanin (APC)-conjugated anti-mouse c-Kit; and PE-conjugated anti-mouse stem 
cell antigen (Sca)-1. The progenitor cell population was analysed using: PE-conjugated anti-














































































































mouse CD127; PE/Cy7-conjugated anti-mouse CD16/32; FITC-conjugated anti-mouse 
CD34; APC-conjugated anti-mouse c-Kit; and APC/Cy7-conjugated anti-mouse Sca-1. After 
initial staining, the cells were washed with 2% (v/v) PBS and resuspended in PerCP-Cy5.5-
conjugated streptavidin (eBioscience, Altrincham, UK) and incubated for a further 15 min at 
4°C. For lineage cell populations, the cells were incubated at 4°C for 20 min with APC-
conjugated anti-mouse B220, FITC-conjugated anti-mouse CD3, PE/Cy7-conjugated anti-
mouse Gr1, PE-conjugated anti-mouse Mac1 and APC/Cy7-conjugated anti-mouse Ter119. 
Following incubation, the cells were washed and resuspended in 2% (v/v) PBS.
The samples were vortexed, filtered (pore size 40 μm) and DAPI stain (20 g/ml) 
added at a 1:100 dilution to all of the SLAM, progenitor and lineage samples in order to 
identify viable cells. A BD LSR Fortessa 4 lasers flow cytometer was then used to assess 
the composition of the cell populations and all possible frequencies were collected from each 
sample. The markers of the hematopoietic cell populations analyzed in this study were: Lin- 
Sca-1+ c-Kit+ (LSK), CD150+ CD48- LSK (hematopoietic stem cell; HSC), CD150- CD48- 
LSK (multipotent progenitors; MPP), CD150- CD48+ LSK (hematopoietic progenitor cell I; 
HPC-I) and CD150+ CD48+ LSK (hematopoietic progenitor cell II; HPC-II) in the SLAM class; 
Lin- Sca-1- c-Kit+ (LK), CD34+ CD16/32- LK (common myeloid progenitor; CMP), CD34- 
CD16/32- LK (megakaryocyte-erythroid progenitor; MEP), CD34+ CD16/32+ LK 
(granulocyte-macrophage progenitor; GMP) and CD127+ (common lymphoid progenitor; 
CLP) in the progenitor class; and GR1+ Mac1- (granulocytes), GR1+ Mac1+ (myeloid-derived 
suppressor cells; MDSC), GR1-Mac1+ (macrophages), B220+ (B-cells), CD3+ (T-cells) and 
Ter119+ (red blood cells) in the lineage class.
2.7. Liver gene expression
Approximately 50 mg of liver was homogenized with 1 ml of RiboZol™ (Amresco LLC, 
Ohio, USA) and total RNA isolated according to the manufacturer’s instructions (Amresco 














































































































LLC, Ohio, USA). The quality of RNA was routinely assessed by determining the A260:A280 
and A260:A230 ratios using NanoDrop 2000 and size-fractionation of an aliquot by agarose 
gel electrophoresis. The RNA (1000 ng) was then reverse transcribed using Moloney Murine 
Leukemia Virus reverse transcriptase according to the manufacturer’s instructions 
(Promega, Southampton, UK). The cDNA (10 ng) was then used for quantitative polymerase 
chain reaction (qPCR) using Atherosclerosis RT2 Profiler PCR Arrays (Qiagen, Manchester, 
UK), which contains primers for 84 atherosclerosis-associated and five housekeeping genes 
together with three negative, three positive and one genomic DNA contamination controls, 
with SYBR Green JumpStartTM Taq ReadymixTM for qPCR. The qPCR array involved a two-
step amplification (melting at 950C for 15 sec and simultaneous annealing/extension at 600C 
for 60 sec) for 45 cycles in LightCycler® 96 Real-Time PCR System (Roche, Welwyn 
Garden City, UK). Gene transcript levels were calculated using the comparative Ct method 
and normalized to five housekeeping genes [β-actin; β-2-microglobulin (B2m); Gapdh; β-
glucuronidase (Gusb); and heat shock protein HSP90β1 (Hsp90ab1)].
2.8. In vitro experiments
Culturing of the human acute monocytic leukemia THP-1 cell line, its differentiation 
into macrophages and treatment with vehicle or physiological concentration of the 
formulation or various active ingredients was carried out as previously described.15 
Production of ROS in vitro was determined using a 2’7’-dichlorofluorescin diacetate 
(DCFDA) Cellular ROS Detection Assay Kit (ab113851) according to the manufacturer’s 
instructions (Abcam, Cambridge, UK). Tert-butyl hydroperoxide (TBHP) was used as a 
positive control for ROS production in cells.















































































































The normality of the data sets was tested using Shapiro-Wilk test, histograms and Q-
Q plots and any data transformations have been stated. Data values outside two standard 
deviations of the mean were classed as outliers and removed before statistical analysis (the 
N numbers are indicated in the appropriate tables or figure legends). To compare the means 
of two groups, either a t-test (normal data distribution) or a Mann-Whitney test (non-normal 
distribution) were used. To compare the means of multiple groups, a One-way analysis of 
variance (ANOVA) was used with appropriate post-hoc tests (Tukeys or Dunnett if there was 
equal variation between the different test groups or Dunnett T3 or Games-Howell post-hoc 
in cases of unequal variation). A generalised linear model (GLM) was used to assess a 
combination of continuous and categorical variables simultaneously and to avoid 
pseudoreplication. Significance was defined as p≤0.05. 
3. Results
3.1. The effect of the formulation on weight parameters and plasma lipid, 
cytokine and oxidant profiles: beneficial effects on plasma cholesterol with 
increased levels of HDL 
Mouse weight gain positively correlated with time (Fig. S1) with the mice gaining 
approximately 0.09 g per day resulting in a total average increase in weight of 1.89 g 
(p<0.001; adj-R2=0.86) over the duration of the study. There was no significant difference in 
the rate of weight gain or the final weight in mice receiving a HFD and the formulation 
compared to those on HFD and the vehicle control, nor was there any significant interaction 
between time and treatment type (Fig. S1). It should be noted that the statistical model used 
determines the change in weight over time by controlling for the impact of the animal's 
starting weight by using a random intercept structure.














































































































The effect of the formulation on the different fat pads was also determined because 
of their important and often distinct roles in atherosclerosis.18 The formulation produced a 
significant increase in the weight of renal fat pad (Fig. S2; p=0.027). In contrast, no 
significant changes were observed in the weight of subcutaneous fat, inguinal fat, gonadal 
fat, interscapular brown adipose tissue, thoracic perivascular adipose tissue (PVAT) or total 
fat (Fig. S2).
Elevated levels of LDL/VLDL and total cholesterol are associated with an increased 
risk of CVD whereas high levels of HDL are considered as anti-atherogenic.2-4 The plasma 
levels of HDL showed a significant increase (p=0.043) following feeding of a HFD with the 
formulation when compared to the vehicle control (Table 1). In addition, the formulation 
produced a trend towards reduction in plasma levels of total cholesterol (p=0.076) and free 
cholesterol (p=0.066) together with a non-significant decrease in LDL/VLDL (Table 1). No 
between group differences were observed for the total cholesterol:HDL and total 
cholesterol:LDL/VLDL ratios but a trend towards a decrease of the LDL/VLDL:HDL ratio 
(p=0.077) was seen in mice receiving the formulation compared to the vehicle control (Table 
1).
The effect of the formulation on plasma TG levels were also determined as this can 
act as an independent risk factor for CVD.10 The formulation significantly increased plasma 
TG levels (p<0.001) compared to the vehicle control (Table 1). The ratios of TG:total 
cholesterol, TG:HDL and TG:LDL/VLDL were also assessed. The TG:total cholesterol and 
TG:LDL/VLDL ratios were also significantly increased (p<0.001 and p=0.004 respectively) 
by the formulation with no significant changes for the TG:HDL ratio (Table 1).
In vitro experiments on human THP-1 macrophages carried out as our previous 
studies15 showed that the formulation (with or without PS) can increase TBHP-induced 
intracellular levels of ROS (Fig. S3). In addition, such in vitro experiments with key active 
ingredients in the formulation showed that the TBHP-induced ROS production in THP-1 














































































































monocytes was significantly increased by EPA and DHA and significantly decreased by 
catechin and β-sitosterol (Fig. S4A). In THP-1 macrophages,  EPA, DHA and campesterol 
treatment significantly increased TBHP-induced ROS production whereas this was 
significantly attenuated by catechin (Fig. S4B). In the light of these findings, the effect of the 
formulation on plasma ROS levels were determined in vivo and no significant differences 
between the groups were observed (Table 1). Increased lipid peroxidation is also pro-
atherogenic and plasma malondialdehyde (MDA), a by-product of lipid peroxidation, is a 
biomarker of oxidative stress.19 The action of the formulation on plasma MDA levels was 
therefore also analyzed and showed an increase in mice receiving the formulation that 
almost reached significance (p=0.053) (Table 1).
The plasma levels of several cytokines were determined because of their crucial roles 
in orchestrating the inflammatory response during atherosclerosis.2,4,5,7 The formulation 
produced a decrease in the plasma levels of several cytokines, including chemokine (C-X-
C motif) ligand (CXCL)1, IL-1, IL-5, IL-6, IL-10 and tumour necrosis factor (TNF)-α, though 
the changes were not significant (Table 1). No significant changes were seen in the ratio of 
pro:inflammatory:anti-inflammatory cytokine levels (data not shown).
3.2. The formulation produces a significant reduction in the frequency of 
macrophages and myeloid-derived suppressor cells (MDSC) within the 
bone marrow of mice fed a HFD
The mature, stem and progenitor cell populations within the bone marrow of mice 
have been found to be altered following feeding of a HFD and changes in bone marrow cell 
populations have also been associated with progression of atherosclerosis and metabolic 
syndrome.20,21 The effect of the formulation on the profile of these cells in the bone marrow 
was therefore determined. The data for the mature cells in the bone marrow are shown in 
Figure 1. The formulation produced a significant decrease in the percentage of 














































































































macrophages (p=0.022, Fig. 1C) and MDSC (p=0.023, Fig. 1D). No significant changes 
were seen for white blood cells (Fig. 1A), T-cells (Fig. 1F) and B-cells (Fig. 1G). For 
hematopoietic stem and progenitor cells, the formulation produced a trend towards decrease 
in the percentage of common lymphoid progenitor (CLP; p=0.083, Fig. 2K) without 
significantly affecting Lin- cKit+ (LK, Fig. 2C), multipotent progenitor cells (MPP, Fig. 2D), 
hematopoietic stem cells (HSC, Fig. 2E), hematopoietic progenitor cells (HPC) II (Fig. 2F), 
HPC I (Fig. 2G), megakaryocyte-erythroid progenitor (MEP, Fig. 2H) granulocyte-
macrophage progenitor (GMP, Fig. 2I) and common myeloid progenitor (CMP, Fig. 2J).  
3.3. The liver expression of several key genes implicated in atherosclerosis and 
metabolic syndrome was altered by the formulation
Liver gene expression has a major impact on changes in metabolism and 
inflammation seen in atherosclerosis and metabolic syndrome.22,23 The Mouse 
Atherosclerosis RT² Profiler PCR Array was therefore used to investigate the effect of the 
formulation on the liver expression of 84 key genes implicated in the disease. Figure 3 shows 
a volcano plot of changes in hepatic gene expression with Table 2 indicating percentage 
changes in the expression of all the genes analyzed. A total of 50 genes out of 84 were 
found to have their expression altered by at least 10% by the formulation. From these, the 
expression of 8 genes was significantly changed by the formulation with that for an additional 
gene, Cd44, almost reaching significance (p=0.051) (highlighted in Fig. 3). The expression 
of five genes was significantly induced by the formulation: anti-atherogenic and anti-
inflammatory transcription factors -nuclear receptor subfamily 1 group H member 3 [Nr1h3; 
also called liver-X-receptor (LXR)-)24 by 16% (p=0.034) and peroxisome proliferator-
activated receptor (PPAR)- (Pparg)25 by 95% (p=0.003); the Lypla1 gene that codes for 
acyl-protein thioesterase 1 (APT1)26, a lipase involved in lipid metabolism by 17% (p=0.011); 
the Sod1 gene that codes for superoxide dismutase (SOD)1, an enzyme capable of 














































































































metabolising ROS27 by 23% (p=0.003); and CASP8 and FADD-like apoptosis regulator 
[Cflar; also called FLICE-like inhibitory protein (c-FLIP)]28 implicated in the regulation of cell 
apoptosis by 35% (p=0.009). In contrast, the expression of three genes was significantly 
attenuated by the formulation: interferon- (Ifng) (implicated in pro-inflammatory 
responses)2,5,6 by 58% (p=0.013); Cxcl1 (codes for pro-inflammatory chemokine)5 by 37% 
(p=0.049); and leukaemia inhibitory factor (Lif) (implicated as anti-atherogenic cytokine)5 by 
58% (p=0.027). The formulation also produced a trend towards reduced expression of genes 
coding for; Cd44 implicated in cell-cell interactions, cell adhesion and migration29 by 23% 
(p=0.051), BCL2 related protein A1 (Bcl2a1a) by 53% (p=0.086), selectin P ligand (Selplg) 
by 26% (p=0.069), basic fibroblast growth factor (Fgf2) by 34% (p=0.078), (Il1β by 37% 
(p=0.060) and Tnf by 44% (p=0.101) (Table 2).
4. Discussion
The anti-atherogenic effects of fish oils, cocoa extracts and PS are well 
documented3,4 but no study has examined the effect of a combination of these active 
ingredients in their natural or most available format in vivo. In this study in C57BL6/J mice 
fed a HFD for 3 weeks, supplementation with the emulsified formulation increased plasma 
HDL levels and improved the LDL/VLDL:HDL ratio (Table 1). Anti-atherogenic effects were 
also observed on cell populations within the bone marrow (e.g. reduced levels of 
macrophages; Fig. 1) together with the beneficial modulation of expression of both pro-and 
anti-atherogenic genes in the liver (e.g. increased expression of anti-atherogenic genes 
Nr1h3, Pparg and Sod1 together with decreased expression of pro-atherogenic genes such 
as Ifng and Cxcl1) (Fig. 3 and Table 2). The study extends our previous in vitro research on 
the protective actions of the formulation on several monocyte/macrophage processes 
associated with atherosclerosis in vitro15 to an in vivo context (e.g. beneficial effects on risk 
factors associated with atherosclerosis and metabolic syndrome such as plasma lipoprotein 














































































































profile, systemic inflammation, hepatic lipid alterations and gene expression) and supports 
further studies on mouse model systems for these diseases and clinical trials.
The formulation had no impact on the weight gain of mice during 3 weeks feeding of 
HFD (Fig. S1). Previous studies on EPA, DHA or fish oils showed no short-term differences 
(3-4 weeks) but a reduction in body weight following 10-12 weeks of feeding30,31 suggesting 
that longer feeding periods may be required for beneficial weight changes. Components of 
the formulation have been shown to impact upon various fat stores within the body though 
the results are not always consistent.31-34 For example, previous studies have found that 
both omega-3 PUFAs and flavanol supplementation resulted in reduced white fat 
accumulation in vivo31,32 whereas others have shown that both flavanols and PS had no 
effect on the size of the white fat deposits.33,34 The only significant change in fat stores 
produced by the formulation was an increase in renal fat weight with a non significant 
reduction in interscapular brown fat and increase in thoracic PVAT (Fig. S2). The expansion 
of PVAT is considered anti-atherogenic as it is known to contribute to fatty acid clearance 
via thermogenesis and reducing inflammation, and loss of PVAT in mouse model systems 
has been associated with increased atherosclerosis.18 On the other hand, reduced weight 
of interscapular brown fat pads has been shown to occur during brown fat activation and 
contributes to the attenuation of atherosclerosis development in mouse model systems.35 
The short term activation of brown fat is associated with increases in TG levels,36 expression 
of Nr1h3 and Pparg 37,38, HDL cholesterol levels36 and lipid perxodation.39 These changes 
are consistent with the findings of our study and thus suggest a potential mechanism that 
needs to be investigated in future studies with model systems involving HFD feeding for 
longer duration (e.g. 12 weeks). 
Increased plasma HDL levels produced by the formulation is a key anti-atherogenic 
event because of its important role in promoting reverse cholesterol transport and acting in 
an anti-inflammatory manner.2-4 Indeed, our previous in vitro study showed that this 














































































































formulation stimulated macrophage cholesterol efflux in vitro.15 Future studies should 
investigate the effect of the formulation on the expression of lipoprotein associated enzymes 
such as phospholipase A2 (HDL-LpPLA2) and paraoxonase-1 (PON1). Studies in mouse 
models of atherosclerosis have also shown that EPA dietary supplementation for 28 days 
increased plasma HDL levels.40 In addition, increased HDL levels were observed in rats and 
mice treated with a flavonol-rich green tea extract or with PS.41,42 In contrast to HDL, the 
formulation produced non-significant reduction of plasma levels of LDL/VLDL (Table 1). This 
finding contradicts previous studies that have shown that omega-3 PUFAs, flavanols and 
PS are all capable of significantly reducing plasma LDL levels.4,42 However, the formulation 
did produce a trend towards reduction of LDL/VLDL:HDL ratio (Table 1) and there is growing 
evidence that assessing LDL or HDL cholesterol levels in isolation is not always associated 
with cardiovascular health and the LDL:HDL ratio is a better clinical risk marker of 
atherosclerosis and sudden cardiac death.43,44 The formulation caused an increase in 
plasma TG levels (Table 1), which is surprising as previous studies have shown that omega-
3 PUFAs and PS reduced circulating TG levels3,4,10,45 though flavanols have failed to 
significantly alter TG levels in both mice and humans.4,5,46 However, TGs are not thought to 
play a direct role in atherosclerosis disease development47 and, as discussed above, 
increased plasma TG levels may be indicative of brown fat activation that is known to protect 
against disease development. The discrepancies also point that combinations of nutritionally 
active ingredients in their natural context have different actions compared to individual 
components, thereby indicating the need for more detailed studies on combination products. 
Several examples of such differences between combination products and individual 
components exist; for example, extra virgin olive oil reduces atherosclerosis in 
apolipoprotein E deficient mouse model system whereas its major polyphenol, 
hydroxytyrosol, increases plaque burden in the same model.48,49 In addition, differential 
effects of EPA and DHA present in fish oils have been documented.50














































































































Several recent in vivo studies have demonstrated that omega-3 PUFAs, flavanols 
and PS dietary supplementation are capable of attenuating oxidative stress.3,4,51,52 Our in 
vitro studies showed that the formulation increased macrophage ROS production (Fig. S3) 
though this was not found to be the case in vivo (Table 1). However, the formulation did 
increase lipid peroxidation, a consequence of increased ROS levels, as measured by 
plasma MDA levels (Table 1). This result differs from other studies which have shown that 
omega-3 PUFAs, PS and flavanols attenuate lipid peroxidation51-53 but further points to 
potential brown fat activation39 that, as detailed above, needs to be investigated as part of 
future research as this is associated with increased Sod1 expression (Table 2) and lipid 
peroxidation (Table 1) as seen in this study. 
The inflammatory response in atherosclerosis is orchestrated by a multitude of 
cytokines.5-8 Dietary supplementation with omega-3 PUFAs, flavanols and PS has been 
found to reduce the circulating levels of CXCL1 and TNF-α in mice.4,54,55 In addition, omega-
3 PUFAs reduced the levels of IL-5 and IL-10 in mice whereas flavanol treatment failed to 
alter IL-10 levels and the effects of PS were more complex with IL-5 levels being attenuated 
and IL-10 levels unaffected.3,4,56-59 In this study, no significant changes in the plasma levels 
of these or other cytokines were observed in response to the formulation and with the 
exception of IFN-, the plasma levels of all the cytokines analyzed were reduced by 
supplementation with the formulation (Table 1). This suggests a dampening of immune 
activation and supports the observed reductions in atherogenic immune cell populations in 
the bone marrow (Fig. 1). Mature, stem and progenitor cell populations within the bone 
marrow of mice have been found to be altered following feeding of a HFD and during the 
development of atherosclerosis.20,21 In this study, the formulation produced a significant 
reduction in the percentage of macrophages and MDSCs within the bone marrow (Fig. 1). 
The pro-atherogenic roles of macrophages in atherosclerosis is well established.5 The role 
of MDSC in inflammation and atherosclerosis is less well defined60 and the reduction on 














































































































their population may be linked to changes in IL-6 and IL-10 (Table 1) that are known to be 
involved in the differentiation of MDSCs.60 
The liver also has a major impact upon inflammation, metabolism and 
atherosclerosis22,23 and the formulation were found to modulate the expression of a number 
of hepatic genes that further supports its anti-atherogenic potential. The expression of five 
genes (Cflar, Lypla1, Nr1h3, Ppard and Sod1) was significantly induced by the formulation. 
CFLAR can prevent cell apoptosis by blocking caspase 8 activation and stimulating nuclear 
factor kappa B (NFκB) and extracellular signal-regulated kinase (ERK) signaling28 and its 
expression is elevated in healthy hearts and reduced following heart failure.61 In addition, 
oxLDL attenuated Cflar expression in vascular endothelial cells leads to apoptosis.61 
Previous research has shown that omega-3 PUFAs promote Cflar expression whereas the 
effects of flavanols and PS are not known.62 The transcription factors NR1H3 (LXR α) and 
PPAR-γ have been demonstrated to have anti-inflammatory and anti-atherogenic 
actions.24,25 Both NR1H3 and PPAR-γ protect against cholesterol accumulation within cells 
by enhancing the expression of genes involved in cholesterol efflux and transportation, and 
attenuating the expression of pro-inflammatory genes, including Tnf-α and Il-1β24,25, which 
is consistent with the apparent reduction in the plasma levels of these cytokines (Table 1). 
NR1H3 activation is also associated with reduced dietary cholesterol absorption from the 
intestine and elevation of HDL cholesterol levels24, and may therefore contribute to our 
observed increase in plasma HDL (Table 1). In addition to regulating cholesterol 
homeostasis, NR1H3 induces the hepatic transcription of several lipogenic enzymes.24 
PPAR- is also well known target for antidiabetic drugs such as thiazolidiniones.25 Thus, 
future studies of HFD feeding of longer duration (e.g. 12 weeks) should investigate the effect 
of the formulation on markers of hepatic steatosis and improvement in glucose homeostasis. 
SOD1 is considered anti-atherogenic because of its ability to neutralize free superoxide 
radicals27 and increased hepatic Sod1 expression in response to the formulation may 














































































































explain in part why ROS generation was not significantly increased in vivo (Table 1) despite 
increases seen in vitro (Fig. S3 and S4) though potential antagonism between different 
active ingredients could have contributed. The enzyme APT1 is encoded by the gene Lypla1 
which was also found to have its expression induced by the formulation (Table 2). Although 
the function of APT1 during atherosclerosis disease development remains unclear, it is 
involved in lipid metabolism (depalmitoylation).26 
From the down regulated genes, the chemokine CXCL1 plays an important role in 
the recruitment of monocytes to the site of oxLDL accumulation in atherosclerosis and its 
circulating levels are increased in patients with coronary artery disease.5 The reduced 
hepatic expression of this gene in our study together with the apparent reduced plasma 
levels (Table 1) is consistent with the decrease in monocyte migration by the formulation 
observed in our previous in vitro study.15 In addition, CD44, ITGB2 and SELPLG are all 
known to play a role in cell recruitment during atherosclerosis.29,63 IFN-γ is an important pro-
atherogenic cytokine and reduced expression of the gene has been observed during in vivo 
assessment of the effects of individual ingredients present in the formulation40,64,65 although 
reductions in the plasma levels of this cytokine were not observed in our study. Finally, not 
all gene expression changes were anti-atherogenic; for example, consistent with previous 
studies on flavanols66, the expression of Lif was also reduced by the formulation (Table 2). 
LIF is able to attenuate endothelial cell proliferation, induce vasorelaxation within arteries by 
increasing nitric oxide production and inhibit vascular smooth muscle cell proliferation.5 
5. Conclusions
This is the first in vivo study to assess the effect of a unique nutritional combination 
containing omega-3 PUFAs, flavanols and PS at a human physiological equivalent dose in 
mice receiving a HFD. The formulation has shown promising potential in reducing risk 
factors associated with atherosclerosis and metabolic syndrome in the light of its ability to 














































































































increase plasma HDL levels, promote an anti-atherogenic cell profile in the bone marrow 
and beneficially impact upon both hepatic gene expression and lipid alterations. 
Furthermore, there is an indication that the formulation is potentially capable of enhancing 
brown fat activation as suggested by changes in gene expression and several other plasma 
parameters that needs to be investigated as part of future studies. 
The number of animals used and the duration of HFD feeding in the current study is 
similar to our previous published research that demonstrated many beneficial anti-
atherogenic changes in risk factors16, some of which were subsequently translated into 
humans.67 Limitations of the current study include the number of animals used, which may 
have contributed in part for some of the trends not reaching statistical significance, the short 
duration of HFD feeding and the use of only male mice. Future studies should be carried out 
on a larger number of both male and female mice (to delineate any gender-specific 
differences), using both short-term HFD feeding as in this study and for a longer period (e.g. 
12 weeks) and compare the action of the formulation with individual components. The 
studies should also be extended to mouse models of atherosclerosis where the efficacy of 
the formulation and individual components to attenuate the development of the disease and 
cause regression of existing plaques can be investigated together with impact on hepatic 
steatosis, glucose homeostasis and brown fat activation. Finally, the efficacy of the 
formulation to reduce CVD burden and associated risk factors should be analyzed in clinical 
trials.
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Table 1. Plasma lipids, oxidative markers and cytokines 
Control Formulation p-Value
Lipids (mg/dL)
TC 159 ± 10 136.7 ± 5.21 0.076
LDL/VLDL 53.59 ± 2.76 47.26 ± 3.32 0.174
HDL 40.12 ± 6.20 56.6 ± 3.45 0.043
TG 20.63 ± 1.16 40.38 ± 40.38 <0.001
FC 31.3 ± 5.66 15.92 ± 4.86 0.066
Lipid Ratios
TC:HDL    5.27 ±  1.83   2.46 ± 0.19 0.157
TC:LDL/VLDL 3.01 ±  0.27 2.94 ± 0.17 0.825
LDL/VLDL:HDL 1.61 ±  0.37 0.86 ± 0.09 0.077
TG:TC 0.15 ±  0.01 0.33 ±  0.04 <0.001
TG:HDL 0.74 ±  0.21 0.80 ±  0.09 0.790






1.00 ±  0.05 1.16 ±  0.13 0.385
MDA (M) 3.48 ±  0.78 7.20 ±  0.51 0.053
Cytokines 
(pg/ml)
CXCL1 159.60 ± 5.20 130.80 ± 13.80 0.106
IFN-γ 0.60 ± 0.20 0.80 ± 0.20 0.583
IL-1β 0.50 ± 0.10 0.40 ± 0.00 0.372
IL-5 2.00 ± 0.70 1.10 ± 0.10 0.243
IL-6 10.10 ± 3.20 5.40 ± 1.00 0.195
IL-10 9.20 ± 1.10 7.20 ± 1.00 0.243
TNF-α 7.50 ± 1.00 6.40 ± 0.30 0.110
Data represents the mean ± SEM from 13 mice (control n=6; formulation n=7) except for cytokines 
where the data represents the mean ± SEM from five (CXCL1 and IL-1β) or six (IFN-γ, IL-5, IL-6, 
IL-10 and TNF-α) control mice and either five (IFN-γ) or six (CXCL1, IL-10, IL-1β, IL-5, IL-6 and 
TNF-α) formulation treated mice (plasma with undetectable assay readings were removed before 
statistical analysis). Statistical analysis was performed using an unpaired Student’s t-test. Values of 
p are stated and considered significant when p0.05.
Abbreviations: TC, total cholesterol; HDL, high-density lipoprotein; LDL/VLDL, low-density 
lipoprotein/very low-density lipoprotein, TG, triglycerides; FC, free cholesterol; ROS, reactive 
oxygen species; MDA, malondialdehyde; IFN, interferon; IL, interleukin; TNF, tumour necrosis 
factor.














































































































Table 2. The effect of the formulation on the expression of several key genes 
implicated in atherosclerosis
                 Control                   Formulation
Gene N      Mean ±SEM N Mean ±SEM % Change p-Value
Abca1 6 1 ±0.04 6 1.13 ±0.07 13  (↑) 0.139
Ace 5 1 ±0.16 6 0.84 ±0.18 16  (↓) 0.516
Apoa1 6 1 ±0.04 6 0.94 ±0.04 6  (↓) 0.285
Apob 6 1 ±0.04 6 1.00 ±0.02 0  (-) 0.977
Apoe 6 1 ±0.07 6 1.05 ±0.08 5  (↑) 0.629
Bax 6 1 ±0.08 6 1.07 ±0.04 7  (↑) 0.462
Bcl2 5 1 ±0.16 6 0.74 ±0.11 26  (↓) 0.210
Bcl2a1a 6 1 ±0.24 6 0.47 ±0.13 53  (↓) 0.086
Bcl2l1 6 1 ±0.04 6 1.08 ±0.09 8  (↑) 0.441
Bid 6 1 ±0.05 6 1.04 ±0.02 4  (↑) 0.512
Birc3 6 1 ±0.03 6 0.94 ±0.05 6  (↓) 0.325
Ccl2 6 1 ±0.12 6 0.84 ±0.18 16  (↓) 0.492
Ccl5 6 1 ±0.21 6 0.76 ±0.09 24  (↓) 0.329
Ccr1 6 1 ±0.35 4 0.50 ±0.17 50  (↓) 0.235
Ccr2 6 1 ±0.21 6 1.29 ±0.18 29  (↑) 0.313
Cd44 6 1 ±0.09 6 0.77 ±0.05 23  (↓) 0.051
Cdh5 6 1 ±0.05 6 0.98 ±0.07 2  (↓) 0.793
Cflar 6 1 ±0.06 6 1.35 ±0.09 35  (↑) 0.009
Col3a1 6 1 ±0.16 6 1.25 ±0.19 25  (↑) 0.329
Csf2 4 1 ±0.32 2 0.77 ±0.34 23  (↓) NA
Ctgf 6 1 ±0.48 6 0.45 ±0.07 55  (↓) 0.310
Cxcl1 6 1 ±0.14 5 0.63 ±0.08 37  (↓) 0.049
Eln 6 1 ±0.14 6 0.89 ±0.12 11  (↓) 0.576
Eng 6 1 ±0.06 6 0.98 ±0.06 2  (↓) 0.858
Fabp3 5 1 ±0.07 6 0.88 ±0.13 12  (↓) 0.452
Fas 6 1 ±0.06 6 1.11 ±0.05 11  (↑) 0.156
Fga 6 1 ±0.04 6 0.92 ±0.03 8  (↓) 0.132
Fgb 6 1 ±0.03 6 0.95 ±0.03 5  (↓) 0.240
Fgf2 6 1 ±0.15 5 0.66 ±0.04 34  (↓) 0.078
Fn1 6 1 ±0.05 6 0.93 ±0.03 7  (↓) 0.240
Hbegf 6 1 ±0.12 6 1.02 ±0.22 2  (↑) 0.944
Icam1 6 1 ±0.08 6 0.93 ±0.05 7  (↓) 0.461
Ifng 5 1 ±0.11 4 0.42 ±0.13 58  (↓) 0.013
Il1a 6 1 ±0.06 6 1.08 ±0.17 8  (↑) 0.668
Il1b 6 1 ±0.14 6 0.63 ±0.10 37  (↓) 0.060
Il1r1 6 1 ±0.09 6 1.18 ±0.24 18  (↑) 0.506
Il1r2 6 1 ±0.20 3 1.07 ±0.20 7  (↑) 0.822














































































































Il2 3 1 ±0.59 3 0.97 ±0.36 3  (↓) 0.970
Il3 4 1 ±0.19 2 0.38 ±0.05 62  (↓) NA
Il4 4 1 ±0.28 4 0.37 ±0.03 63  (↓) 0.111
Il5 3 1 ±0.44 3 0.23 ±0.03 77  (↓) 0.225
Itga2 5 1 ±0.13 4 0.97 ±0.30 3  (↓) 0.919
Itga5 6 1 ±0.09 6 1.28 ±0.13 28  (↑) 0.108
Itgax 6 1 ±0.23 6 0.81 ±0.15 19  (↓) 0.500
Itgb2 6 1 ±0.08 6 0.84 ±0.03 16  (↓) 0.104
Kdr 6 1 ±0.05 6 0.97 ±0.03 3  (↓) 0.693
Klf2 0 NA 0 NA NA NA
Lama1 6 1 ±0.10 6 1.05 ±0.07 5  (↑) 0.725
Ldlr 6 1 ±0.05 6 1.20 ±0.10 20  (↑) 0.123
Lif 6 1 ±0.19 5 0.42 ±0.08 58  (↓) 0.027
Lpl 6 1 ±0.11 6 1.12 ±0.16 12  (↑) 0.531
Lypla1 6 1 ±0.04 6 1.17 ±0.02 17  (↑) 0.011
Mmp1a 6 1 ±0.13 6 1.17 ±0.16 17  (↑) 0.436
Mmp3 5 1 ±0.35 3 0.67 ±0.24 33  (↓) 0.466
Msr1 6 1 ±0.04 6 0.96 ±0.08 4  (↓) 0.670
Nfkb1 6 1 ±0.03 6 1.07 ±0.03 7  (↑) 0.102
Npy 1 1 ±NA 0 NA NA NA
Nr1h3 6 1 ±0.05 6 1.16 ±0.03 16  (↑) 0.034
Pdgfa 6 1 ±0.10 6 1.06 ±0.12 6  (↑) 0.696
Pdgfb 6 1 ±0.11 6 0.80 ±0.04 20  (↓) 0.128
Pdgfrb 6 1 ±0.07 5 1.03 ±0.02 3  (↑) 0.729
Plin2 6 1 ±0.09 6 1.11 ±0.06 11  (↑) 0.330
Ppara 6 1 ±0.08 6 1.13 ±0.09 13  (↑) 0.317
Ppard 6 1 ±0.07 6 0.99 ±0.02 1  (↓) 0.857
Pparg 6 1 ±0.10 6 1.95 ±0.20 95  (↑) 0.003
Ptgs1 6 1 ±0.04 6 1.01 ±0.06 1  (↑) 0.935
Rxra 6 1 ±0.04 6 1.13 ±0.06 13  (↑) 0.134
Sele 5 1 ±0.31 6 1.08 ±0.19 8  (↑) 0.842
Sell 5 1 ±0.45 6 0.71 ±0.24 29  (↓) 0.590
Selp 6 1 ±0.05 6 0.94 ±0.06 6  (↓) 0.420
Selpg 6 1 ±0.11 6 0.74 ±0.04 26  (↓) 0.069
Serpinb2 4 1 ±0.29 4 0.45 ±0.16 55  (↓) 0.164
Serpine1 6 1 ±0.09 6 1.24 ±0.15 24  (↑) 0.213
Sod1 6 1 ±0.05 6 1.23 ±0.03 23  (↑) 0.003
Spp1 6 1 ±0.10 6 1.11 ±0.09 11  (↑) 0.422
Tgfb1 6 1 ±0.05 6 1.09 ±0.07 9  (↑) 0.310
Tgfb2 5 1 ±0.30 6 0.82 ±0.15 18  (↓) 0.625
Thbs4 5 1 ±0.52 0 NA NA NA
Tnc 6 1 ±0.21 6 1.24 ±0.19 24  (↑) 0.409














































































































Gene transcript levels were assessed in the livers of mice after 21 days of HFD and treatment with either a vehicle control 
or the formulation. Gene transcript levels were calculated using the comparative Ct method and normalized to five 
housekeeping genes (Actb, B2m, Gapdh, Gusb and Hsp90ab1) with values from the vehicle treated mice given an arbitrary 
value of 1. Samples from mice with undetectable Ct readings were removed before statistical analysis (p values from the 
analysis are indicated). The percentage change in expression of each gene are shown with ↑ indicating induction and ↓ 
showing reduction in expression. Abbreviations: Abca1, ATP-binding cassette, subfamily A (ABC1), member 1; Ace, 
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1; Actb, -actin; Apoa1, apolipoprotein A-I; Apob, apolipoprotein 
B; Apoe, apolipoprotein E; B2m, -2-microglobulin; Bax, BCL2-associated X protein; Bcl2, B cell leukemia/lymphoma 1; 
Bcl2a1a (Bfl-1, A1), B cell leukemia/lymphoma 2 related protein A1a; Bcl2I1 (Bcl-XL), BCL2-like 1; Bid, BH3 interacting 
domain death agonist; Birc3 (cIAP1, cIAP2), buculoviral IAP repeat-containing 3; Ccl2 (MCP-1), chemokine (C-C motif) 
ligand 2; Ccl5 (RANTES), chemokine (C-C motif) ligand 5; Ccr1, chemokine (C-C motif) receptor 1; Cdh5, cadherin 5; 
Ccr2, chemokine (C-C motif) receptor 2; Cd44, CD44 antigen; Cflar (Casper), CASP8 and FADD-like apoptosis regulator; 
Col3a1, collagen, type III, 1; Cxcl1 (Gro1), chemokine (C-X-C motif) ligand 1; Csf2 (GMCSF), colony stimulating factor 2 
(granulocyte-macrophage); Ctgf, connective tissue growth factor; Eln, elastin; Eng1 (Evi-1), endoglin; Fabp3, fatty acid 
binding protein 3, muscle and heart; Fas (TNFRSF6), TNF receptor superfamily member 6; Fga, fibrinogen  chain; Fgb, 
fibrinogen  chain; Fgf2 (bFGF), fibroblast growth factor 2;  Fn1, fibronectin 1; Gapdh, glyceraldehyde 3-phosphate 
dehydrogenase; Gusb, -glucoronidase; Hbegf (Dtr), heparin-binding EGF-like growth factor; Hsp90ab1, heat shock 
protein 90; Icam1, intercellular adhesion molecule 1; Ifng, interferon-; Il1a, interleukin-1; Il1b, interleukin-1; Il1r1, 
interleukin 1 receptor, type I; Il1r2, interleukin 1 receptor, type II;  Il2, interleukin-2; ll3, interleukin-3; Il4, interleukin-4; Il5, 
interleukin-5; Itga2, integrin 2; Itga5, integrin  5 (fibronectin receptor ); Itgax, integrin  X; Itgb2, integrin 2; Kdr 
(VEGFR2), kinase insert domain protein receptor; Klf2, kruppel-like factor 2 (lung); Lama1, laminin 1; Ldlr, low density 
lipoprotein receptor; Lif, leukemia inhibitory factor; Lpl, lipoprotein lipase; Lypla1, lysophospholipase 1;  Mmp1a, matrix 
metallopeptidase 1a (interstitial collagenase); Mmp3, matrix metallopeptidase 3; Msr1, macrophage scavenger receptor 1; 
Nfkb1, nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105;  Npy, neuropeptide Y; Nr1h3, nuclear 
receptor subfamily 1, h group H, member 3; Pdgf, platelet derived growth factor ; Pdgfb, platelet derived growth factor, 
B polypeptide; Pdgfrb, platelet derived growth factor receptor, beta polypeptide; Plin2, perlipin 2; Ppara, peroxisome 
proliferator activated receptor ; Ppard, peroxisome proliferator activated receptor ; Pparg, peroxisome proliferator 
activated receptor ; Ptgs1 (COX1), prostaglandin-endoperoxide synthase 1; Rxra, retinoid X receptor ; Sele, selectin, 
endothelial cells; Sell (LECAM-1), selectin, lymphocyte; Selp, selectin, platelet; Sod1, superoxide dismutase 1; Selplg (P-
Selectin), selectin, platelet (p-selectin) ligand; Serpinb2 (PAI-2), serine (or cysteine) peptidase inhibitor, clade B, member 
2; Serpine1 (PAI-1), serine (or cysteine) peptidase inhibitor, clade B, member 1; Spp1, secreted phosphoprotein 1; Tgfb1, 
transforming growth factor-1; Tgfb2, transforming growth factor-1; Thbs4, thrombospondin 4; Tnc, tenascin C; Tnf, tumor 
necrosis factor; Tnfaip3, tumor necrosis factor, alpha-induced protein 3; Vcam1, vascular cell adhesion molecule 1; Vegfa, 
vascular endothelial growth factor A; Vwf, Von Willebrand factor  
Tnf 6 1 ±0.20 5 0.56 ±0.14 44  (↓) 0.101
Tnfaip3 6 1 ±0.12 6 1.03 ±0.22 3  (↑) 0.905
Vcam1 6 1 ±0.07 6 0.97 ±0.08 3  (↓) 0.788
VeffA 6 1 ±0.09 6 1.10 ±0.07 10  (↑) 0.410
Vwf 6 1 ±0.16 6 0.71 ±0.05 29  (↓) 0.127
Actb 6 1 ±0.02 6 1.08 ±0.06 8  (↑) NA
B2m 6 1 ±0.05 6 0.95 ±0.01 5  (↓) NA
Gapdh 6 1 ±0.04 6 0.92 ±0.03 8  (↓) NA
Gusb 6 1 ±0.04 6 0.98 ±0.05 2  (↓) NA
Hsp90ab1 6 1 ±0.03 6 1.09 ±0.04 9  (↑) NA















































































































Figure 1. The formulation decreases the frequency of macrophages and MDSCs 
within the bone marrow 
Cell populations were assessed in the bone marrow of mice after 21 days of a HFD 
and treatment with either a vehicle control or the formulation. (A) a bar graph showing 
numbers of white blood cells; (B) representative flow cytometry plot of macrophages and 
MDSCs; (C) frequency of macrophages in the bone marrow; (D) frequency of MDSCs in the 
bone marrow; (E) representative flow cytometry plot of T/B cells; (F) frequency of T cells in 
the bone marrow; and (G) frequency of B-cells in the bone marrow. The data in graphs are 
mean ± SEM from six control and seven formulation treated mice. Statistical analysis was 
performed using an unpaired Student’s t-test (A, D, F and G) or Mann Whitney U test (C) 
where * p≤0.05.
Figure 2. The effect of the formulation on hematopoietic stem and progenitor cells 
within the bone marrow 
Cell populations were assessed in the bone marrow of mice after 21 days of a HFD 
and treatment with either a vehicle control (A) or the formulation (B). Representative flow 
cytometry plots of hematopoietic stem and progenitor cells in the bone marrow are 
presented (A-B). The bar graphs show the frequency of LK cells (C), MPP cells (D), HSC 
(E), HPCII cells (F), HPCI cells (G), MEP cells (H), GMP cells (I), CMP cells (J) and CLP 
cells (K) in the bone marrow. The data in graphs are mean ± SEM from six control and seven 
formulation treated mice (the various cell populations represent only a small proportion of 
starting cells). Statistical analysis was performed using an unpaired Student’s t-test (C, D, 
E, G, H, I, J, K) or Mann Whitney U test (F) and p values stated where appropriate. 
Abbreviations: CLP, common lymphoid progenitor; CMP, common myeloid progenitor; 
GMP, granulocyte-macrophage progenitor; HPC, hematopoietic progenitor cell; HSC, 














































































































hematopoietic stem cells; LK, Lin- c-Kit+ cells; MEP, megakaryocyte-erythroid progenitor; 
MPP, multipotent progenitors.
Figure 3. Volcano plot showing global gene expression changes in the liver of mice 
fed a HFD and treated with the formulation or vehicle control
Gene transcript levels of 84 genes were assessed in the livers of mice after 21 days 
of a HFD and treatment with either a vehicle control or the formulation. The data are 
presented as the mean formulation induced fold change when compared to the vehicle 
control treated mice. All genes present on the Qiagen RT2 profiler PCR Array were plotted. 
The log fold change following the treatment vs the vehicle control cells is represented on the 
x-axis. The y-axis shows the -log10 of the p value. A p value of 0.05 (dashed line) and a fold 
changes of ±10% (solid lines) are indicated. Genes whose expression was significantly 
altered by the formulation are indicated by a black triangle. Abbreviations: Cd44, CD44 
antigen; Cflar, CASP8 and FADD-like apoptosis regulator; Cxcl1, Chemokine (C-X-C motif) 
ligand 1; Ifng, interferon-; Lif, leukemia inhibitory factor; Lypla1, lysophospholipase 1; 
Nr1h3, nuclear receptor subfamily 1; Pparg, peroxisome proliferator activator receptor-; 
Sod1, superoxide dismutase 1. 
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